What “Accretive” and “Dilutive” Actually Mean in an M&A Deal

Accretive means pro forma EPS goes up. That's the whole definition. The interesting part is why it goes up, why that's a much weaker statement about the deal than most candidates assume, and how to run the numbers in your head.

A deal is accretive if the acquirer's earnings per share is higher after the acquisition than it was before. Dilutive if it's lower.

That's it. No judgment about whether the deal was smart, no claim about value created. Just a comparison of two EPS figures.

Candidates get the definition right and then fall apart on the follow-up, which is always some version of why. So work the arithmetic once and the follow-ups stop being scary.

The two numbers you're comparing

Standalone EPS is the acquirer's net income divided by its share count. Pro forma EPS is the combined company's net income divided by the combined share count. Both sides of that fraction can move, and the deal structure decides which ones do.

• The numerator picks up the target's net income, plus any synergies, minus the after-tax cost of whatever paid for the deal — new interest expense on acquisition debt, or interest income given up on cash spent.
• The denominator only moves if the acquirer issues new shares. An all-cash or all-debt deal leaves the share count alone.

Compare the new EPS to the old one. Higher is accretive. That single sentence is the entire framework, and everything below is just plugging things into it.

A clean all-stock example

Acquirer earns $100mm of net income on 100mm shares, so EPS is $1.00. The stock trades at $20, which is a 20x P/E. Target earns $20mm and gets bought for $300mm of the acquirer's stock — a 15x P/E paid.

At $20 a share, $300mm of stock means 15mm new shares issued.

Accretive, by about 4%. And notice you could have called it before doing any of that: the acquirer trades at 20x and paid 15x. In an all-stock deal, that comparison is the whole answer.

Why the P/E rule works

Flip both multiples upside down. A 20x P/E is a 5% earnings yield — each share the acquirer issues is worth $20 and carries $1.00 of earnings behind it. The target was bought at 15x, a 6.7% earnings yield, so every dollar of stock handed over brought back more earnings than that dollar of stock was already producing.

Earnings per share goes up because the acquirer bought earnings more cheaply than the market prices its own.

Reverse it and the rule reverses too. Same acquirer at 20x, but the target now costs $500mm for its $20mm of earnings — 25x. That's 25mm new shares against $120mm of combined income, or $0.96 of pro forma EPS. Dilutive by 4%.

Cash and debt deals

No new shares here, so the denominator is frozen and all the action is in the numerator. The question becomes what the money used to be earning.

Take the same $300mm purchase, funded entirely with debt at a 6% interest rate and a 25% tax rate. Interest expense is $18mm a year pre-tax, which is $13.5mm after the tax shield.

Accretive by 6.5%, and more accretive than the stock version of the identical deal. The same logic as before explains it: the after-tax cost of the debt is 6% × (1 − 25%), or 4.5%, and the target's earnings yield at the price paid is 6.7%. Buying a 6.7% yield with 4.5% money adds to EPS.

An all-cash deal works the same way, except the cost is the interest income the acquirer stops earning on the cash it just spent. Since cash sitting on a balance sheet usually earns less than acquisition debt costs, all-cash deals tend to be the most accretive of the three — which is exactly why so few interview answers should stop at “it's accretive.”

What accretion doesn't tell you

This is the part interviewers are usually fishing for.

A company trading at a high multiple can buy almost any cheaper company and produce accretion. The target could be shrinking, capital-hungry, and in a dying end market. The arithmetic doesn't care. It compares two multiples and a financing cost, and it says nothing about whether the price paid was defensible or whether the two businesses have any reason to be under the same roof.

The reverse trap matters just as much. A dilutive deal isn't automatically a bad one. Paying up for a fast-growing target can hurt EPS in year one and look obviously correct by year four, which is why bankers run accretion/dilution across several forecast years rather than one, and why the year the deal crosses into accretion gets its own line in the pitch.

EPS is an accounting output. Value comes from cash flows and the price paid for them. Say that out loud in an interview and you've answered a question they hadn't asked yet.

The adjustments that get skipped

A real model doesn't just add the two net income lines together. The ones worth knowing by name:

• Incremental intangible amortization. Part of the purchase price gets allocated to identifiable intangibles that are then amortized, and that amortization is a real drag on pro forma earnings. See purchase price allocation for how the allocation itself works.
• Synergies, usually cost synergies, tax-effected before they hit net income. Revenue synergies get modeled far less often and believed far less than that.
• The target's own existing interest expense, which usually disappears if the acquirer refinances the target's debt as part of the deal.
• Transaction and financing fees. Advisory fees are typically expensed and treated as one-time, while financing fees get capitalized and amortized over the life of the debt.

One thing that isn't an adjustment: goodwill. Under US GAAP, public companies don't amortize goodwill — it sits on the balance sheet and gets tested for impairment. Identifiable intangibles with finite lives are the ones that amortize. Mixing those two up is a common and very audible mistake.

Breakeven synergies

Once you can spot a dilutive deal, the natural follow-up is how much synergy it would take to fix. It's a two-step calculation.

Go back to the dilutive stock deal: 125mm pro forma shares, $120mm of combined net income, $0.96 of EPS against a $1.00 standalone. Holding EPS flat at $1.00 across 125mm shares needs $125mm of net income, so the shortfall is $5mm after tax. Gross that back up at the 25% tax rate — $5mm / (1 − 25%) — and you need about $6.7mm of pre-tax synergies to get the deal to neutral.

Then the judgment question, which is the one actually being asked: is $6.7mm of annual cost savings plausible out of a business earning $20mm? Sometimes obviously yes. Sometimes the number quietly tells you the price was too high.

How it gets asked

Mistakes that show up under a clock

• Forgetting to tax-effect the interest expense or the synergies. Both hit the income statement above net income, so both get taxed.
• Adding shares in a cash deal. If no stock is issued, the denominator doesn't move.
• Comparing pro forma net income to standalone net income instead of comparing EPS to EPS. Combined net income is almost always higher; that isn't accretion.
• Treating goodwill as an amortizing expense.
• Answering “accretive” as though it settles whether the deal was good. It doesn't, and the interviewer is usually waiting to see if you know that.

Accretion/dilution is one of the few technical topics where the arithmetic is genuinely easy and the follow-up questions are genuinely hard. Get the mechanics automatic so your attention is free for the part that's actually being scored.

For the pieces underneath — how the purchase price gets carved up, and how the enterprise-value bridge decides what a buyer is really paying for — start with the concept guides, then come back and run these numbers again without notes.